SCHEMBL31378682

SCHEMBL31378682

O=c1[nH]c2cc(F)c(F)cc2cc1[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 6/20 0.52
GRIN3B O60391 6/20 0.52
GRIN1 Q05586 6/20 0.52
GRIN2A Q12879 6/20 0.52
GRIN2B Q13224 6/20 0.52
GRIN2C Q14957 6/20 0.52
GRIN3A Q8TCU5 6/20 0.52
GRIA1 P42261 3/20 0.52
GRIA2 P42262 3/20 0.52
GRIA3 P42263 3/20 0.52
GRIA4 P48058 3/20 0.52
CYP1A2 P05177 2/20 0.52
MAPT P10636 2/20 0.52
GRIK1 P39086 2/20 0.52
GRIK2 Q13002 2/20 0.52
GRIK3 Q13003 2/20 0.52
GRIK4 Q16099 2/20 0.52
GRIK5 Q16478 2/20 0.52
LMNA P02545 1/20 0.52
CYP3A4 P08684 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31378922 0.80 DAO (0.57) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL31378960 0.80 DAO (0.57) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL4704610 0.77 GRIA2 (0.74) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL29548054 0.74 GRIN2D (0.53) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL1770636 0.74 GRIN2D (0.53) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL23674923 0.73 ATM (0.43) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL8222975 0.73 GRIA1 (0.49) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL5795638 0.73 DAO (0.57) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL30723724 0.73 ATM (0.43) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL7264691 0.73 GRIA2 (0.49) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171431-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-05-29 US disclosed
WO-2025030163-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171431-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE IGF1R, TRHR, TSHR GRIN2D 3840/4885GRIN3B 2634/4885GRIN1 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.